| 9.39 0.05 (0.54%) | 08-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.08 |
1-year : | 14.11 |
| Resists | First : | 10.35 |
Second : | 12.08 |
| Pivot price | 9.61  |
|||
| Supports | First : | 9.11 |
Second : | 8.35 |
| MAs | MA(5) : | 9.51 |
MA(20) : | 9.6 |
| MA(100) : | 9.12 |
MA(250) : | 13.27 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 18.5 |
D(3) : | 27 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 20.45 | Low : | 7.21 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADMA ] has closed above bottom band by 23.7%. Bollinger Bands are 54.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.53 - 9.6 | 9.6 - 9.66 |
| Low: | 9.18 - 9.26 | 9.26 - 9.32 |
| Close: | 9.23 - 9.36 | 9.36 - 9.45 |
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Mon, 31 Aug 2026
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring A Promising 82% Potential Upside - DirectorsTalk Interviews
Wed, 26 Aug 2026
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
Wed, 26 Aug 2026
Law firm probes ADMA Biologics' leadership for possible breaches of fiduciary duty to shareholders - Pluang
Wed, 12 Aug 2026
ADMA Biologics: The Earnings Reset Still Leaves More Upside (NASDAQ:ADMA) - Seeking Alpha
Mon, 10 Aug 2026
ADMA Biologics, Inc. (ADMA) Class Action Lawsuit: Investors Face August 10, 2026, Deadline - PR Newswire
Thu, 06 Aug 2026
ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 224 (M) |
| Shares Float | 220 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 93.2 (%) |
| Shares Short | 21,920 (K) |
| Shares Short P.Month | 24,230 (K) |
| EPS | 0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.8 |
| Profit Margin | 32.9 % |
| Operating Margin | -123.4 % |
| Return on Assets (ttm) | 21.7 % |
| Return on Equity (ttm) | 41.9 % |
| Qtrly Rev. Growth | 15.8 % |
| Gross Profit (p.s.) | 1.47 |
| Sales Per Share | 2.28 |
| EBITDA (p.s.) | 1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 137 (M) |
| Levered Free Cash Flow | 55 (M) |
| PE Ratio | 13.41 |
| PEG Ratio | 0 |
| Price to Book value | 5.18 |
| Price to Sales | 4.1 |
| Price to Cash Flow | 15.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|